These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 12223105)

  • 1. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
    Braun J; Sieper J
    Arthritis Res; 2002; 4(5):307-21. PubMed ID: 12223105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
    Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
    Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.
    Braun J; van der Heijde D
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1097-109. PubMed ID: 12831346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-TNF-alpha treatment and spondyloarthropathies].
    Braun Y; Balbir-Gurman A
    Harefuah; 2002 Nov; 141(11):965-8, 1010. PubMed ID: 12476631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Caspi D; Reitblatt T; Charboneau D; Rubins JB
    Semin Arthritis Rheum; 2004 Feb; 33(4):283-8. PubMed ID: 14978666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.
    De Keyser F; Baeten D; Van den Bosch F; Kruithof E; Verbruggen G; Mielants H; Veys E
    Drugs; 2004; 64(24):2793-811. PubMed ID: 15563249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy for ankylosing spondylitis: new treatment modalities.
    Braun J; Breban M; Maksymowych WP
    Best Pract Res Clin Rheumatol; 2002 Sep; 16(4):631-51. PubMed ID: 12406431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF antagonists for ankylosing spondylitis.
    Drug Ther Bull; 2005 Mar; 43(3):19-22. PubMed ID: 15762384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.
    Sieper J; Braun J
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii58-61. PubMed ID: 11890656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides.
    Braun J; Baraliakos X; Brandt J; Sieper J
    Scand J Rheumatol; 2005; 34(3):178-90. PubMed ID: 16134723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
    Haberhauer G; Strehblow C; Fasching P
    Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].
    Langer HE
    Wien Med Wochenschr; 2008; 158(7-8):200-5. PubMed ID: 18500471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies in the treatment of spondyloarthritis.
    Maksymowych WP
    Expert Opin Investig Drugs; 2002 Jul; 11(7):937-46. PubMed ID: 12084004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.